Lek, a Sandoz company, receives its 13th TOP 10 Award
- In 2014 Lek, a Sandoz company, provided more than 187 thousand hours of education and training attended by all employees to a various degree.
- Sandoz Management Academy, which was launched last year in Lek, a Sandoz company, proved to be a very successful form of education. The Academy is a program designed for managers.
- As an international pharmaceutical company, Lek has an immense advantage in education and training of associates. The company has access to a broad spectrum of knowledge, various forms of education, and the opportunity to take part in international projects.
Lek Pharmaceuticals, a Sandoz company, received the TOP 10 Education Management Award for the 13th time in a row. Planet GV and the Education Management Institute Sofos award ten Slovenian companies, which invested the most intensely and systematically in the education of employees over the last year.
In 2014, Lek, a Sandoz company, provided more than 187 thousand hours of education and training attended by all associates to various extents. Most training and education was focused on statutory and mandatory education, business skills and foreign languages. On average, our employees had 5.16 days of training and education, and a total of 7.81 days of the year including compulsory education in the workplace.
“Our employees and continuous development of their talents are the future of our business. We are constantly looking for ways to remain successful in the years ahead. Educational guidelines are based on our business strategy and reflected in the goals of each employee. Employees and managers plan their own development and career together based on goals. Educated employees can take on more demanding tasks and – reinforced by new knowledge – implement our vision and mission,” explained Jasna Kos, Head of Learning & Training at Lek, a Sandoz company.
The pharmaceutical industry is a knowledge-based industry. Continuous investment in training and education of our employees is therefore crucial for our business to be successful and to achieve the set aims and objectives. In this regard, diverse knowledge, in particular knowledge of new technologies and products, as well as systematic development of managers undergoing local and global education and other forms of business skills development are of great importance at Lek, a Sandoz company. The funds allocated for education and development of employees remained unchanged, despite the increasingly restrictive economic and financial situation.
Sandoz Management Academy – special training for managers
As an international pharmaceutical company, Lek has an immense advantage in education and training of associates. The company has access to a broad spectrum of knowledge, various forms of education, and the opportunity to take part in international projects that offer our employees a unique opportunity to learn and gain experience.
“Among novelties introduced over the past year is the Sandoz Management Academy, which proved to be a very successful form of education. This is a programme for managers featuring specific and adapted content on how to be a good leader in Sandoz. The training consists of many individual and group tutorials and ends with a development plan for each individual, subsequently integrated into the personal development application”, added Jasna Kos.
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/en.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Sandoz also holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal.
Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32